华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600521 华海药业

已收盘 09-26 15:00:00

{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":16.89,"timestamp":1727334000000,"preClose":16.61,"halted":0,"volume":18689374,"delay":0,"floatShares":1467000000,"shares":1467000000,"eps":0.6888,"marketStatus":"已收盘","marketStatusCode":5,"change":0.28,"latestTime":"09-26 15:00:00","open":16.61,"high":16.89,"low":16.44,"amount":312000000,"amplitude":0.0271,"askPrice":16.9,"askSize":938,"bidPrice":16.89,"bidSize":108,"shortable":0,"etf":0,"ttmEps":0.6888,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1727400600000},"adr":0,"adjPreClose":16.61,"symbolType":"stock","openAndCloseTimeList":[[1727314200000,1727321400000],[1727326800000,1727334000000]],"highLimit":18.27,"lowLimit":14.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1466755454,"pbRate":2.89,"roa":"--","roe":"8.88%","epsLYR":0.57,"committee":-0.438435,"marketValue":24773000000,"floatMarketCap":24773000000,"peRate":24.520907,"changeRate":0.0169,"turnoverRate":0.0127,"status":0},"requestUrl":"/m/hq/s/600521/tweets","defaultTab":"tweets","newsList":[{"id":"2470678013","title":"华海药业：\n2024年上半年公司制剂业务实现销售收入约31.46亿元，同比增长约18.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470678013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470678013?lang=zh_cn&edition=full","pubTime":"2024-09-26 20:00","pubTimestamp":1727352015,"startTime":"0","endTime":"0","summary":"证券之星消息，华海药业(600521)09月26日在投资者关系平台上答复投资者关心的问题。投资者：公司2024年上半年制剂生产了多少亿片？2024年上半年美国制剂生产了多少亿片？华海药业董秘：您好，感谢您对公司的关注和支持！2024年上半年公司制剂业务实现销售收入约31.46亿元，同比增长约18.66%。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092600031806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0070","600521","BK0028","BK0239","BK0188","BK0185","BK0201"],"gpt_icon":0},{"id":"2470256831","title":"华海药业二甲双胍恩格列净片获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256831","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256831?lang=zh_cn&edition=full","pubTime":"2024-09-25 19:48","pubTimestamp":1727264880,"startTime":"0","endTime":"0","summary":"新京报讯9月25日，华海药业发布公告，近日收到国家药监局核准签发的二甲双胍恩格列净片 、二甲双胍恩格列净片的《药品注册证书》。截至目前，公司在二甲双胍恩格列净片剂产品研发项目上已投入研发费用约1637万元。目前，国内获得二甲双胍恩格列净片剂产品注册证书的厂家有齐鲁制药有限公司、杭州中美华东制药有限公司等。根据米内数据库预测，二甲双胍恩格列净片剂产品2023年国内市场销售金额约2.2亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925194909a1dc7502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925194909a1dc7502&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0070","BK0201","BK0028","BK0188","BK0185","BK0012","600521"],"gpt_icon":0},{"id":"2470239261","title":"华海药业(600521.SH)获二甲双胍恩格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2470239261","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470239261?lang=zh_cn&edition=full","pubTime":"2024-09-25 17:55","pubTimestamp":1727258153,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的二甲双胍恩格列净片(V)、二甲双胍恩格列净片(VI)的《药品注册证书》，本次获批的产品用于配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0201","BK0239","600521","BK0185","BK0188","BK0028","BK0070"],"gpt_icon":0},{"id":"2470046184","title":"华海药业大幅上涨 生物医药行业创新发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2470046184","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470046184?lang=zh_cn&edition=full","pubTime":"2024-09-25 13:04","pubTimestamp":1727240694,"startTime":"0","endTime":"0","summary":"消息解读2024年上半年生物医药行业上市公司的半年报显示，创新和“出海”是行业发展的方向。2024年上半年，处于产业转型期的生物医药行业展现出多个亮点，重点表现在创新药收入占比持续增大、多家公司新药出海授权金额不断创新高等方面。多家生物医药企业在半年报中披露了创新药研发的重要进展。主营业务及业绩华海药业公司主营业务为多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925130524a1dc5f4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925130524a1dc5f4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161726","399441","BK0028","BK0185","BK0188","600521","BK0239","BK0070","BK0012","BK0201"],"gpt_icon":0},{"id":"2469453133","title":"华海药业09月24日获主力加仓1894万元 环比增加398.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469453133","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469453133?lang=zh_cn&edition=full","pubTime":"2024-09-24 15:19","pubTimestamp":1727162357,"startTime":"0","endTime":"0","summary":"09月24日, 华海药业股价涨2.10%，报收16.01元，成交金额1.94亿元，换手率0.83%，振幅3.19%，量比1.36。华海药业今日主力资金净流入1894万元，上一交易日主力净流入380万元，今日环比增加398.42%。|09月24日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|兆日科技|4.99%|#|弘业期货|4.87%|#|汇金科技|4.03%|#|跨境通|3.88%|#|中信海直|3.26%|#|安硕信息|3.24%|#|威领股份|3.20%|#|首创证券|3.15%|#|盛德鑫泰|2.90%|#|上海九百|2.82%|华海药业所在的化学制药行业，今日主力净流入2.69亿元，行业排名31/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240924153603957982b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240924153603957982b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0070","600521","BK0028","BK0239","BK0188","BK0185","BK0201"],"gpt_icon":0},{"id":"2468044615","title":"【获批】华海药业大丰收，900万喜提两个畅销新品","url":"https://stock-news.laohu8.com/highlight/detail?id=2468044615","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468044615?lang=zh_cn&edition=full","pubTime":"2024-09-20 16:06","pubTimestamp":1726819572,"startTime":"0","endTime":"0","summary":"精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。在中国三大终端六大市场，阿立哌唑口服溶液的销售额呈现快速增长态势，2023年增幅达87.54%，销售额已超过5000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0012","600521","BK0188","BK0028","BK0201","BK0070","BK0185"],"gpt_icon":0},{"id":"2468730383","title":"华海药业：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2468730383","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468730383?lang=zh_cn&edition=full","pubTime":"2024-09-18 17:23","pubTimestamp":1726651402,"startTime":"0","endTime":"0","summary":"每经AI快讯，华海药业 9月18日晚间发布公告称，浙江华海药业股份有限公司及下属控股子公司长兴制药股份有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》。2023年1至12月份，华海药业的营业收入构成为：成品药销售占比59.35%，原材料及中间体销售占比38.03%，技术服务占比1.47%，其他行业占比0.36%，进出口贸易占比0.06%。截至发稿，华海药业市值为237亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409181723429f04c709&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409181723429f04c709&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0028","BK0012","600521","BK0188","BK0201","BK0185","BK0070"],"gpt_icon":0},{"id":"2468308977","title":"华海药业(600521.SH)获马来酸依那普利片与阿立哌唑口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2468308977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468308977?lang=zh_cn&edition=full","pubTime":"2024-09-18 17:21","pubTimestamp":1726651274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业 发布公告，公司及下属控股子公司长兴制药股份有限公司于近日收到国家药品监督管理局核准签发的马来酸依那普利片与阿立哌唑口服溶液《药品注册证书》。阿立哌唑口服溶液主要用于治疗13～17岁青少年和成人的精神分裂症。本次公司的马来酸依那普利片、子公司长兴制药的阿立哌唑口服溶液获得国家药监局的《药品注册证书》，进一步丰富了公司的产品线，有助于提升公司产品的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600521","BK0188","BK0201","BK0185","BK0239","BK0028","BK0012","BK0070"],"gpt_icon":0},{"id":"2468088833","title":"华海药业最新公告：获得马来酸依那普利片和阿立哌唑口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2468088833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468088833?lang=zh_cn&edition=full","pubTime":"2024-09-18 17:11","pubTimestamp":1726650669,"startTime":"0","endTime":"0","summary":"华海药业公告，公司及控股子公司长兴制药近日收到国家药监局核准签发的《药品注册证书》。马来酸依那普利片主要用于治疗各期原发性高血压、肾血管性高血压、各级心力衰竭等疾病，预计2023年国内市场销售金额约2.58亿元。阿立哌唑口服溶液主要用于治疗13～17岁青少年和成人的精神分裂症，预计2023年国内市场销售金额约5557万元。上述产品的注册批准可视同通过一致性评价，有助于提升公司产品的市场竞争力。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091800024187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0185","600521","BK0028","BK0070","BK0201","BK0188"],"gpt_icon":0},{"id":"2468393631","title":"华海药业获得发明专利授权：“一种普瑞巴林的结晶方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2468393631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468393631?lang=zh_cn&edition=full","pubTime":"2024-09-18 02:15","pubTimestamp":1726596932,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示华海药业新获得一项发明专利授权，专利名为“一种普瑞巴林的结晶方法”，专利申请号为CN202111152597.8，授权日为2024年9月17日。今年以来华海药业新获得专利授权26个，较去年同期减少了70.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091800001065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0201","BK0028","BK0188","BK0185","BK0012","600521"],"gpt_icon":0},{"id":"2467488765","title":"华海药业拟募资不超12.1亿，定增不超1.5亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2467488765","media":"地产k线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467488765?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:37","pubTimestamp":1726191450,"startTime":"0","endTime":"0","summary":"华海药业（600521）近日披露了向特定对象发行股票的募集说明书，计划募资总额不超12.1亿元，发行股票上限为1.5亿股，约占发行前总股本的30%。此次发行面向不超过35名符合条件的法人及自然人投资者，实际控制人及高管不参与。募集资金将主要用于制剂数字化智能制造项目，预计投入9.3亿元，占总投资13.2亿元的近七成，其余2.8亿元则用于补充流动资金。项目预计实现内部收益率23.76%，静态投资回收期7.08年，经济效益与社会效益显著。公司表示，若实际募资不足，将调整投资项目及资金使用顺序，缺口由公司自筹解决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130949159ef936e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130949159ef936e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","BK0201","BK0028","BK0188","BK0239","BK0185","BK0012","BK0070"],"gpt_icon":0},{"id":"2466275882","title":"华海药业最新公告：公司制剂产品白消安注射液获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2466275882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466275882?lang=zh_cn&edition=full","pubTime":"2024-09-12 19:21","pubTimestamp":1726140061,"startTime":"0","endTime":"0","summary":"华海药业公告，公司向美国FDA申报的白消安注射液的新药简略申请（ANDA）已获得批准且获得孤儿药认定。白消安注射液主要用于与环磷酰胺联合使用，作为慢性粒细胞白血病异基因造血祖细胞移植前的预处理方案。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091200031823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0070","600521","BK0028","BK0239","BK0188","BK0185","BK0201"],"gpt_icon":0},{"id":"2466273134","title":"华海药业(600521.SH)：白消安注射液获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2466273134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466273134?lang=zh_cn&edition=full","pubTime":"2024-09-12 19:15","pubTimestamp":1726139756,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，公司收到美国食品药品监督管理局(简称“美国FDA”)的通知，公司向美国FDA申报的白消安注射液的新药简略申请(ANDA，即美国仿制药申请)已获得批准且获得孤儿药认定。孤儿药又称罕见病药，是指用于预防、治疗、诊断罕见病的药品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1182648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0012","600521","BK0188","BK0201","BK0185","BK0070"],"gpt_icon":0},{"id":"2464344697","title":"华海药业09月04日主力资金流出181万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2464344697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464344697?lang=zh_cn&edition=full","pubTime":"2024-09-04 15:19","pubTimestamp":1725434373,"startTime":"0","endTime":"0","summary":"09月04日, 华海药业股价涨0.85%，报收16.57元，成交金额2.24亿元，换手率0.92%，振幅4.02%，量比1.12。华海药业今日主力资金净流出181万元，连续3日净流出，上一交易日主力净流出1802万元，今日环比减少89.96%。该股近5个交易日下跌1.84%，主力资金累计净流出572万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出4942万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090415395795e12f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090415395795e12f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","BK0188","BK0239","BK0028","BK0012","BK0070","BK0185","600521"],"gpt_icon":0},{"id":"2464887267","title":"开源证券：给予华海药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2464887267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464887267?lang=zh_cn&edition=full","pubTime":"2024-09-03 19:20","pubTimestamp":1725362433,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对华海药业进行研究并发布了研究报告《公司信息更新报告：2024上半年业绩快速增长，国内制剂业务强劲增长》，本报告对华海药业给出买入评级，当前股价为16.43元。我们看好公司的长期发展，维持公司的盈利预测，预计公司2024-2026年归母净利润为13.04/15.55/19.29亿元，当前股价对应PE为18.8/15.8/12.7倍，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为23.54。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300032003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","161027"],"gpt_icon":0},{"id":"2464828287","title":"华海药业09月03日遭主力抛售1802万元 环比增加2806.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2464828287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464828287?lang=zh_cn&edition=full","pubTime":"2024-09-03 15:17","pubTimestamp":1725347855,"startTime":"0","endTime":"0","summary":"09月03日, 华海药业股价跌1.73%，报收16.43元，成交金额2.65亿元，换手率1.09%，振幅3.47%，量比1.65。华海药业今日主力资金净流出1802万元，上一交易日主力净流出62万元，今日环比增加2806.45%。该股近5个交易日下跌2.90%，主力资金累计净流出326万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出6151万元，其中净流出天数为14日。净流出前三个股分别为人福医药、华海药业、健友股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409031522269edbd7cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409031522269edbd7cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","BK0028","600521","BK0012","BK0185","BK0070","BK0239","BK0188"],"gpt_icon":0},{"id":"2464070822","title":"华海药业(600521)2024年中报点评：单季度业绩创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2464070822","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464070822?lang=zh_cn&edition=full","pubTime":"2024-09-02 00:00","pubTimestamp":1725206400,"startTime":"0","endTime":"0","summary":"单二季度收入和归母净利润均创历史新高。毛利率端，今年上半年原料药毛利率提升5 个百分比，我们预计主要是因为产品结构变化所致，低毛利率的沙坦类品种随着价格下降产品收入占比下降。截至6 月30 日，公司共有70余个制剂产品获国内注册批件，在研项目超120 个，公司正逐步向百余个制剂批文的目标稳步前进。同时，公司新产品亦在稳定导入，24H1 公司共计获批3 个ANDA 文号和1 个暂时批准文号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409021331369f70e793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409021331369f70e793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0070","BK0028","BK0012","BK0201","BK0185","BK0239","600521"],"gpt_icon":0},{"id":"2463285787","title":"华海药业最新公告：公司制剂产品获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2463285787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463285787?lang=zh_cn&edition=full","pubTime":"2024-08-30 18:39","pubTimestamp":1725014390,"startTime":"0","endTime":"0","summary":"华海药业公告称，公司向美国FDA申报的甲磺酸沙芬酰胺片的新药简略申请（ANDA）获得正式批准，恩格列净片和卡格列净片的新药简略申请获得暂时批准。甲磺酸沙芬酰胺片主要用于治疗帕金森，恩格列净片主要用于治疗心力衰竭，卡格列净片主要用于治疗糖尿病。这些批准将有利于公司扩大美国市场销售和强化产品供应链，对公司的经营业绩产生积极影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000038268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0012","600521","BK0188","BK0201","BK0185","BK0070"],"gpt_icon":0},{"id":"2463781769","title":"华海药业(600521.SH)发上半年业绩，净利润7.49亿元，同比增长31.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463781769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463781769?lang=zh_cn&edition=full","pubTime":"2024-08-30 18:10","pubTimestamp":1725012630,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布2024年半年度报告，报告期内公司实现营业收入51.28亿元，同比增长19.43%;归属于上市公司股东的净利润7.49亿元，同比增长31.60%;归属于上市公司股东扣除非经常性损益净利润7.65亿元，同比增长18.00%;基本每股收益0.52元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1176647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600521"],"gpt_icon":0},{"id":"2463786199","title":"华海药业：2024年半年度净利润约7.49亿元，同比增加31.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463786199","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463786199?lang=zh_cn&edition=full","pubTime":"2024-08-30 17:27","pubTimestamp":1725010069,"startTime":"0","endTime":"0","summary":"每经AI快讯，华海药业 8月30日晚间发布半年度业绩报告称，2024年上半年营业收入约51.28亿元，同比增加19.43%；归属于上市公司股东的净利润约7.49亿元，同比增加31.6%；基本每股收益0.52元，同比增加33.33%。截至发稿，华海药业市值为247亿元。道达号“个股趋势”提醒：1. 华海药业近30日内北向资金持股量增加756.28万股，占流通股比例增加0.52%；2. 近30日内无机构对华海药业进行调研。行业深陷价格战，“直播价卖得比很多机构进货价都低”，还有大佬跨界入局……","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024083017423395d2f44a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024083017423395d2f44a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥","stockEarnings":[{"period":"1week","weight":0.0556},{"period":"1month","weight":-0.0018},{"period":"3month","weight":0.002},{"period":"6month","weight":0.3244},{"period":"1year","weight":-0.0004},{"period":"ytd","weight":0.1646}],"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","perCapita":"24841股","boardName":"医药制造业","registeredCapital":"146675万元","compareEarnings":[{"period":"1week","weight":0.0968},{"period":"1month","weight":0.0534},{"period":"3month","weight":0.0113},{"period":"6month","weight":-0.0132},{"period":"1year","weight":-0.0342},{"period":"ytd","weight":0.0087}],"survey":"　　浙江华海药业股份有限公司主营业务为多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品有心血管类、精神障碍类、神经系统类、抗感染类等为主导的产品系列。2023年4月，公司荣获“全国五一劳动奖状”和“浙江省五一劳动奖状”，同月，公司被浙江省药品检查中心认定为浙江省职业检查“尖兵领航”工程实训基地；2023年6月，公司入选米内网颁发的2022年度中国化药企业百强等。","serverTime":1727387105299,"listedPrice":15.55,"stockholders":"59045人(较上一季度减少18.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}